Azad, Tej D. http://orcid.org/0000-0001-7823-4294
Nanjo, Shigeki http://orcid.org/0000-0001-8356-9849
Jin, Michael C.
Chabon, Jacob J.
Kurtz, David M.
Chaudhuri, Aadel A. http://orcid.org/0000-0003-3115-3061
Connolly, Ian D.
Hui, Angela Bik-Yu
Liu, Chih Long http://orcid.org/0000-0002-6577-5427
Merriott, David
Ko, Ryan http://orcid.org/0000-0002-2123-9702
Yoo, Christopher
Carter, Justin
Chen, Emily
Bonilla, Rene
Hata, Akito
Katakami, Nobuyuki
Irie, Kei
Yano, Seiji
Okimoto, Ross http://orcid.org/0000-0002-4467-8476
Bivona, Trever G. http://orcid.org/0000-0001-5734-4128
Newman, Aaron M. http://orcid.org/0000-0002-1857-8172
Iv, Michael
Nagpal, Seema http://orcid.org/0000-0002-0289-2319
Gephart, Melanie Hayden http://orcid.org/0000-0003-2965-9231
Alizadeh, Ash A. http://orcid.org/0000-0002-5153-5625
Diehn, Maximilian http://orcid.org/0000-0003-2032-0581
Funding for this research was provided by:
Doris Duke Charitable Foundation
Japanese Respiratory Society
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA254179, R01CA188298)
Virginia and D.K. Ludwig Fund for Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute
US National Institutes of Health Director’s New Innovator Award Program, CRK Faculty Scholar Fund,
Article History
Received: 3 July 2023
Accepted: 28 March 2024
First Online: 28 May 2024
Competing interests
: A.M.N., A.A.A., and M.D. are co-inventors on patent applications related to cancer biomarkers. A.M.N. reports consultancy with CiberMed. A.A.A. and M.D. are consultants for Genentech and Roche. J.J.C. served as a consultant with Lexent Bio. A.A.A. has served as a consultant for Chugai, Gilead, and Celgene. A.A.A. reports ownership interest in CiberMed and FortySeven. M.D. has served as a consultant for AstraZeneca, Novartis, Bristol Myers Squibb, Gritstone Oncology, and Boehringer Ingelheim. M.D. and A.A.C. have received research funding from Varian Medical Systems. M.D. has received research funding from Illumina. S.N. has received research funding from AstraZeneca. M.D. and A.A.A. report ownership interests in CiberMed and Foresight Diagnostics.